Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

1.160 -0.030 (-2.52%)
Streaming Delayed Price Updated: 10:14 AM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
First data on blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and intraductal papillary mucinous neoplasms (IPMN) differentiation to be presented in San Diego 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Provides Review of 2025 Highlights
From Mainz BioMed NV
Via GlobeNewswire
News headline image
DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
DNA-based Colorectal Cancer Screening as a Home Test 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and Ecuador 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Attend 2025 Maxim Growth Summit
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Study Demonstrated a Sensitivity of 100% and Specificity of 95% 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
Company Provides Update on eAArly DETECT 2 Study 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
CARE currently cooperates with 19 health insurance companies in Germany in the field of colorectal cancer screening 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
Company Advances its Progress toward FDA Premarket Approval Study for its Next Generation Colorectal Cancer Screening Product and Makes a Strategic Acquisition in the Field of Pancreatic Cancer... 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Study is Intended to Verify Previous Discovery Results Demonstrating Sensitivity of 95% and Specificity of 98% 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Enters into Technology Partnership with EDX Medical Group
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Expands into Switzerland with labor team w
Partnership to Launch DNA-Based Colorectal Cancer Screening Test 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
Updated Screening Guidelines Ensure Broader Access to Colorectal Cancer Screening in Germany 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA Approval 
From Mainz BioMed NV
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.